Relief Therapeutics Holding AG (RLFTF)

[aGuyUS]

Bachem Posts Record Sales

BACHEM RECORD SALES IN H1 2020

Bachem Group today reported record sales in H1 2020, demonstrating its strength and reliability during the COVID-19 pandemic.
Bachem is also confirming its guidance. For 2020, the Group is targeting sales growth of over 20% compared to 2019, with an increase in operating profit.
“We are pleased to report impressive revenue growth and a strong EBIT margin in H1, despite the COVID-19 pandemic,” said Thomas Meier, Chief Executive Officer at Bachem. “Based on our excellent peptide pipeline and the promising oligonucleotide market, Bachem is targeting annual sales of over 500mn CHF in the next three years.”
To provide the basis for future growth, Bachem is also investing heavily in capacity throughout 2020. In addition, thanks to strong demand and an excellent flow of incoming orders, the company has created more than 150 new positions in the first half of the year.
Targeted measures were implemented across the organization in H1 to keep our employees safe, ensure business continuity and product supply.
We are proud of the efforts of our employees during the COVID-19 pandemic and would like to take this opportunity to thank them.